Jefferies Initiates Coverage On Lycia Therapeutics with Buy Rating, Announces Price Target of $50

Benzinga · 2d ago
Jefferies analyst Faisal Khurshid initiates coverage on Lycia Therapeutics (NASDAQ:LYCA) with a Buy rating and announces Price Target of $50.